Familial hypercholesterolaemia (FH) is the most common and serious monogenic disorder of lipoprotein metabolism that leads to premature coronary heart disease.
Introduction

Familial hypercholesterolaemia
Familial hypercholesterolaemia (FH) is a relatively common genetic disorder that is associated with premature coronary heart disease (CHD) [1, 2] . In Australia, at least 65,000 people are estimated to have FH with the vast majority of cases remaining undiagnosed, and in many diagnosed cases, patients are receiving inadequate treatment [1, 3] . A patient registry to store clinical and family data is essential to the effective provision of services [4] [5] [6] [7] , and is therefore a vital component of the FH model of care for Australasia [3] and integrated guidance of care for FH [8] . A recent global 'call to arms' by the European Atherosclerosis Society FH Studies Collaboration also emphasises the importance of FH registries worldwide [9] .
The Registry Framework
Recently, we presented an open source disease Rare Disease Registry Framework (RDRF), that allows the efficient deployment of web-based registries that can be modified dynamically as requirements evolve [10, 11] . The RDRF empowers registry administrators to construct registries with minimal software developer effort, by allowing users to dynamically create all data elements (DEs) that define a patient registry and to share DEs across registries. Registries are described in a computerreadable text file, which allows a registry definition to be imported/exported, versioned, and stored in a shared accessible environment.
The RDRF takes a conceptual approach to the design and development of patient registries to ensure access, security, privacy, and to meet the need for harmonisation across multiple clinical sites in a given country, or internationally. The RDRF also fulfills the key criteria required for sustainable registry development [12] [13] [14] [15] , and continues to evolve since first described by Bellgard et al. [10, 11, 13, 16] .
We describe the deployment of the FH Australasia Network Registry utilising the RDRF. The primary purpose of the FH Australasia Network Registry is to collate data to facilitate clinical service planning, and to inform clinical best practice [4] . The registry will also enable research on aggregated data, and the identification of eligible volunteers for clinical trials.
Materials and Methods
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Governance and access to patient data
The FH Australasia Network Registry is governed by a National Advisory Board appointed from expert members from Australia and New Zealand of the FH Australasia Network, which is a subcommittee of the Australasian Atherosclerosis Society. The National Advisory Board, which has a Chairman and a Custodian elected by members of the Board, oversees the governance of the registry and is responsible for all registry activities and reviewing all requests for access to data. All projects sanctioned by the Board are conditional on approval by a recognised authoritative body in the relevant jurisdiction in which the investigation will be undertaken. Access to the registry is co-ordinated by the registry co-ordinator (assigned by the National Advisory Board) who is responsible for overarching data curation, cross-site co-ordination, and arranging processes for data extraction. The registry co-ordinator provides access to the registry through the provision of password protected user accounts to authorized data curators. patients were registered and assigned to a "working group", which is their jurisdictional clinical service. The RDRF has multiple levels of access (Appendix A), with the ability to assign different users to selected working groups. Only the registry co-ordinator has administration privileges, and therefore access to patient data from all jurisdictions.
Requests for access to data by third-parties are regulated through the National Advisory Board. Provision of de-identified data is subject to approval by a jurisdiction human research ethics committee, recommendation by the National Advisory Board, approval of the data custodian (assigned by the National Advisory Board) and the study objectives being aligned with Registry objectives. and nginx (nginx.org/). Django provides distinct levels of inbuilt security, including secure socket layer (SSL) security (encrypts all web traffic to and from the application), cross-site request forgery (CSRF) checking, login restrictions of all views, with the RDRF utilising the Django secure package middleware with all settings enabled by default. The RDRF also stores identifying patient demographic data in a distinct database to any clinical data (Fig. 1) [11, 13, 16] . The source code for the RDRF is available at https://github.com/muccg/rdrf.
Capture of patient data
The demographics and clinical information for each patient are captured by the 'Demographics' and 'Consents' modules and six additional Forms titled Clinical Data, Medications, Genetic Data, Imaging, Apheresis and Follow Up (Fig. 2) .
Currently, all DEs requested by the International FH Consortium are included in the FH Australasia Network registry (see Appendix B for a detailed list of all current Data Elements). 
New features and enhancements
iv) FH Pedigree Module;
Collates information on the number of first, second, and third degree relatives, and allows a file containing a family pedigree to be uploaded and stored. This section is configured to appear only on the Demographics Form of Index Patients. There is potential for a pedigree-drawing tool to be developed and included in the registry at a later date.
Conclusions
The FH Australasia Network Registry provides supporting infrastructure in four key areas: i) addressing a current gap in the flow of data for measuring the quality of healthcare; ii) supporting basic research through the provision of highquality, de-identified data; iii) enabling geographically equitable access to clinical trials; and iv) promulgating information about best practice and care services [4] . The valuable data captured by this registry will inform research, clinical decision making, educational programmes, and ultimately improve the quality of care for FH patients. 
